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Abstract— Diseases are often umbrella terms for many 
subcategories of disease. The identification of these subcategories is 
vital if we are to develop personalised treatments that are better 
focussed on individual patients. In this short paper, we explore the use 
of a combination of unsupervised learning to identify potential 
subclasses, and supervised learning to build models for better 
predicting a number of different health outcomes for patients that 
suffer from systemic sclerosis, a rare chronic connective tissue 
disorder - but one that shares many characteristics with other 
diseases. We explore a number of different algorithms for 
constructing models that simultaneously predict health outcomes and 
identify subcategories. 
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I.  INTRODUCTION 
Different diseases can affect people in different ways. 
There are a number of reasons for this. Firstly, disease 
categories are often “umbrella” terms for a group of 
subcategories of disease. Take Systemic Sclerosis (SSc), 
which is a relatively rare disease (overall incidence of up to 
56 cases/million/year). It is a chronic connective tissue 
disorder, affecting the skin, peripheral circulation and 
multiple internal organs [1]. What is more, it can be 
classified into two major subsets - limited cutaneous SSc, 
where skin thickness affects only areas distal to elbows and 
knees and diffuse cutaneous SSc, where skin involvement 
can affect the whole body. Of course, these are unlikely to 
be the only subcategories and discovering others will be 
essential if we are to make more informed diagnoses.  
 
Fig. 1. Rodnan skin score (from Wigley FM: Systemic sclerosis: Clinical 
features. In Klippel JH, Dieppe PA (eds): Rheumatology, vol. 2, 2nd 2000.) 
Secondly, people respond in different ways to the same 
disease. For example, in SSc some patients are more affected with 
complications in the lungs, whilst others are in the kidneys, heart 
or gastro-intestinal system. Patients undergo regular assessments, 
including history of symptoms, physical examination and a range 
of blood and internal organ tests. Extent and severity of skin 
tightness is measured by modified Rodnan skin score - see Figure 
1, ranging between 0 (normal) and 3 (severe thickening).  
Additionally, results from lung function tests are measured 
regularly. These tests, in combination with other patient 
characteristics that do not change over time (e.g. serological 
markers, age at onset, etc.), can be used as predictors of organ 
complication / mortality. Whilst systemic sclerosis is a rare disease 
it shares traits that are common to many diseases: firstly, variability 
in progression between different individuals, including subclasses 
of disease that can inform how an individual will progress. 
Secondly, the eventual progression to an advance stage with 
similar advance-stage symptoms. In this paper we explore the use 
of classification methods to predict different disease outcomes 
using a combination of clinical indicators related to SSc. We use 
unsupervised methods to preprocess patients into different cohorts 
to identify variations in symptoms and improve classification. This 
discovery of subtypes of disease is becoming popular [2]. 
Previously we explored a variation of Naïve Bayes for disovery of 
glaucoma subtypes [3]. Here we focus on a general approach for 
any classifier. 
II. METHODS 
We use data on 700 SSc patients with baseline demographic 
and clinical characteristics and organ complications including 
modified Rodnan skin score. We explore three classifiers but focus 
on CN2 rules [3] in order to identify relevant clinical tests / 
demographics that are pertinent to disease outcome. This is due to 
the transparent nature of rule based methods. We explore a number 
of different experimental architectures: 
i) no_unsup - Standard k-fold cross-validation classification. 
This involves using the different disease outcomes as class 
variables and other test data / demographics as predictors. 
ii) unsup - K-fold cross-validation classification with 
unsupervised pre-processing. This involves applying a pre-
processing stage whereby all patients are clustered using k-means 
with no class information. 
iii) unsup-class - As (ii) but the class information from the 
training data is used to bias the clustering. The idea is that this will 
help to further refine the clusters so that they are not overly biased 
along the class variable. In other words, it is envisaged that the 
clusters will represent more fine-grain clusters within the different 
classes. 
III. RESULTS 
Figure 2 shows the performance (Area Under ROC Curve) of 
the three different approaches to classification of patients: using 
standard classification (no_unsup), using classification with 
preprocessing using unsupervised learning on the clinical test data 
only (unsup), and finally using unsupervised learning on the 
clinical test data and the class data that is available for training 
(unsup_class). These are assessed using three classifiers (Naïve 
Bayes, Support Vector Machine and CN2) for two disease 
outcomes: time to death from diagnosis (T2RIP) and time to 
Pulmonary Hypertension (T2PAH). 
 
Fig. 2. Classification Area Under Curve (AUC) Comparison 
It is clear that the use of unsupervised clustering prior to 
classification has improved the predictive capabilities of all three 
classifiers. In particular, the basic unsupervised clustering that 
doesn’t take the class into account (unsup) seems to have improved 
prediction the most. This was unexpected as it was thought that 
incorporation of class information (unsup_class) would focus on 
more informative clusters, though it could be that class information 
creates more risk of irrelevant clusters from overfitting. 
Nevertheless, both improve upon standard classification 
(no_unsup). Figure 3 shows some example rules discovered using 
CN2 from the unsup_class experiments. Notice how the 
discovered subclasses of disease are exploited in the rules that 
result in improved accuracy. In particular Cluster C2 is often 
associated with another confounding feature to predict time to 
death greater than 147 months (T2RIP=1), whilst Cluster C3 is 
associated with features that predict shorter times to death 
(T2RIP=0). It is this incorporation of subcategory information that 
is improving prediction accuracy. 
We now explore the general characteristics of these subcategories 
in detail. Figure 4 shows the breakdown of the discovered 
subcategories. Notice that the first cluster is mostly limited SSc, 
whilst clusters 2 and 3 are predominantly diffuse. Also notice that 
cluster 2, which appears in many rules (e.g. see Figure 3), is 
characterized by FVC and DLCO tests with values mostly in the 
higher quartiles, whilst cluster 3 is characterized by low FVC and 
DLCO scores. These characteristics are key to assisting the 
classifiers in improving accuracy and allow us to explore the 
interaction between features within cohorts that have different 
FVC and DLCO test results. 
 
Fig. 3. Example CN2 Rules for Predicting Time to Death > 147 months 
(T2RIP=1) 
 
Fig. 4. Cluster Characteristics for Diffuse vs Limited SSC (subtype) and 
Forced Vital Capacity (FVC) and CO Diffusion Capacity (DLCO) 
IV. CONCLUSIONS 
In this short paper, we have introduced a simple framework for 
improving classification models by incorporating subcategory 
identification in two ways. We have tested these methods for 
predicting outcome for patients diagnosed with systemic sclerosis 
and show that subcategory discovery not only improves prediction 
but that the discovered rules incorporate subcategory information 
that can be directly interpreted to better understand the meaning of 
the new subtypes of disease. 
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Rule quality Coverage Rule 
0.88 14 IF Cluster=C3 AND Abs=4 THEN T2RIP=0 
0.88 27 IF Cluster=C3 AND subset=0 THEN T2RIP=0 
0.87 19 IF Cluster=C3 AND Hb=1 AND Cr=4 THEN T2RIP=0 
0.86 24 IF Cluster=C3 AND Abs=3 THEN T2RIP=0 
0.85 29 IF Cluster=C3 and DLCO=1 THEN T2RIP=0 
0.81 36 IF Cluster=C2 AND Cr=3 THEN T2RIP=1 
0.81 111 IF Cluster=C3 THEN T2RIP=0 
0.79 33 IF age=4 AND Hb=1 THEN T2RIP=0 
0.77 47 IF Cluster=C2 AND Hb=4 THEN T2RIP=1 
0.76 51 IF Cluster=C2 AND Abs=1 THEN T2RIP=1 
0.75 28 IF age=4 AND FVC=1 THEN T2RIP=0 
 
